SLC32A1 Antibody
Description
Structure and Function
-
Protein Target: SLC32A1 (VGAT) is a multi-pass membrane protein with a calculated molecular weight of 57 kDa . It localizes to synaptic vesicles in GABAergic and glycinergic neurons, enabling the storage and release of inhibitory neurotransmitters .
-
Antibody Specificity:
-
Proteintech 14471-1-AP: Targets the full-length SLC32A1 protein via an antigen-affinity purified polyclonal rabbit IgG .
-
Assay Genie CAB3129: Reacts with a recombinant fusion protein spanning amino acids 1–525 of human SLC32A1 .
-
Antibodies-Online ABIN2855225: Recognizes the N-terminal region (AA 14–118) of VGAT .
-
Applications in Research
The SLC32A1 antibody is validated for multiple techniques:
Research Highlights:
-
Neurodegeneration: SLC32A1 antibodies identified GABAergic depletion in Alzheimer’s disease models .
-
Toxicology: Demonstrated fluoride-induced anxiety-like behaviors via disrupted GABAergic signaling .
-
Genetic Disorders: De novo SLC32A1 variants linked to developmental and epileptic encephalopathy .
Clinical Relevance
SLC32A1 dysfunction is implicated in:
-
Epilepsy: De novo missense variants cause developmental and epileptic encephalopathy with intellectual disability and movement disorders .
-
Schizophrenia: Altered GABAergic signaling linked to cortical circuit deficits .
-
Parkinson’s Disease: VGAT downregulation correlates with reduced inhibitory neurotransmission .
Product Specs
Target Background
- Studies have shown that SLC32A1 is present in horizontal cells of the adult outer retina, both at their terminals and throughout the entire cell. PMID: 12115694
- Research has indicated that individuals with schizophrenia exhibit reduced expression of GABA transporter 1 (SLC32A1). PMID: 17471287
